SCHEMBL13617155

SCHEMBL13617155

CC(C)(C)CCCNc1ccc(C#N)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 9/20 0.43
DPP7 Q9UHL4 2/20 0.43
GSK3B P49841 2/20 0.41
DPP8 Q6V1X1 1/20 0.41
IDH1 O75874 3/20 0.40
CCR6 P51684 1/20 0.38
HCAR3 P49019 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
RPS6KB1 P23443 1/20 0.37
CDK2 P24941 1/20 0.37
GSK3A P49840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15471096 0.91 DPP4 (0.45) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL14996239 0.83 HCAR3 (0.54) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL6638863 0.82 DPP4 (0.53) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL9405308 0.82 HCAR3 (0.55) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL3115089 0.80 CHEK1 (0.52) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL3627699 0.80 DPP4 (0.46) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL1725026 0.80 CHEK1 (0.52) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL3049238 0.80 HCAR3 (0.51) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL8352280 0.79 CHEK1 (0.48) DPP4DPP7GSK3BDPP8IDH1
SCHEMBL27303609 0.79 EGLN2 (0.48) DPP4DPP7GSK3BDPP8IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 DPP4 16/4885DPP7 20/4885GSK3B 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.